| Literature DB >> 27979832 |
Marco Demaria1,2, Monique N O'Leary3, Jianhui Chang4, Lijian Shao4, Su Liu3, Fatouma Alimirah3, Kristin Koenig3, Catherine Le3, Natalia Mitin5, Allison M Deal6, Shani Alston6, Emmeline C Academia3, Sumner Kilmarx3, Alexis Valdovinos3, Boshi Wang2, Alain de Bruin7,8, Brian K Kennedy3, Simon Melov3, Daohong Zhou4, Norman E Sharpless6, Hyman Muss6, Judith Campisi1,9.
Abstract
Cellular senescence suppresses cancer by irreversibly arresting cell proliferation. Senescent cells acquire a proinflammatory senescence-associated secretory phenotype. Many genotoxic chemotherapies target proliferating cells nonspecifically, often with adverse reactions. In accord with prior work, we show that several chemotherapeutic drugs induce senescence of primary murine and human cells. Using a transgenic mouse that permits tracking and eliminating senescent cells, we show that therapy-induced senescent (TIS) cells persist and contribute to local and systemic inflammation. Eliminating TIS cells reduced several short- and long-term effects of the drugs, including bone marrow suppression, cardiac dysfunction, cancer recurrence, and physical activity and strength. Consistent with our findings in mice, the risk of chemotherapy-induced fatigue was significantly greater in humans with increased expression of a senescence marker in T cells prior to chemotherapy. These findings suggest that senescent cells can cause certain chemotherapy side effects, providing a new target to reduce the toxicity of anticancer treatments. SIGNIFICANCE: Many genotoxic chemotherapies have debilitating side effects and also induce cellular senescence in normal tissues. The senescent cells remain chronically present where they can promote local and systemic inflammation that causes or exacerbates many side effects of the chemotherapy. Cancer Discov; 7(2); 165-76. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 115. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27979832 PMCID: PMC5296251 DOI: 10.1158/2159-8290.CD-16-0241
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397